This review article examined limited clinical data of PBT for non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in pediatric and young adult populations. The authors made recommendations to consider PBT for 1) young children (younger than 3 or 6 years) in order to minimize the risk of long-term side effects, 2) the sites of head–neck, craniofacial, intraabdominal, pelvic, and paravertebral regions, 3) radioresistant histotypes such as malignant peripheral nerve sheath tumors (MPNSTs), 4) patients associated with genetic syndromes like neurofibromatosis type 1(NF1) due to the increased risk of radiation-induced carcinogenesis. The authors concluded that although PBT’s superiority compared to other modern photon techniques remains to be demonstrated, PBT should be considered as a valid option for patients with NRSTS.